The Furosemide Stress Test, Electrolytes Response and Renal Index in Critically Ill Patients

December 29, 2019 updated by: Davide Chiumello, Hospital San Paolo
Aim of the present study is to compare the response to furosemide stress test in term of diuresis and electrolytes and of the renal index in mechanically ventilated patients at admission and after 3 days in patients with and without the presence of AKI

Study Overview

Status

Completed

Conditions

Detailed Description

The acute kidney injury (AKI) is a common clinical syndrome in critically ill patients, occurring in up of 60% of the patients, and almost 40% of these patients will die within 90 days . Between 5% to 10% of the patients with AKI requires renal replacement therapy and only 30% will be alive after 5 years . The most common reported contributing factors to AKI were sepsis, major surgery, cardiogenic shock, hypovolemia and potentially related drugs . Although the AKI has been classically defined as an abrupt and sustained decrease in renal function and is commonly assessed on serum creatinine rise and/or fall in urine output there are not clear cutoffs for the diagnosis . Unfortunately the changes in these two parameters are poor predicting of AKI in critically ill patients . In the recent years several renal biomarkers have been proposed to accurately detect acute tubular injury before serum creatinine changes with possible improvement in the outcome; however the evidence was quite low . Because the majority of early AKI are related to an acute tubular injury, it has been suggested to evaluate the tubular function reserve by a bolus of furosemide (i.e. the furosemide stress test). As an organic acid, furosemide is tightly bound to serum proteins and gains access to the tubular urinary space through active secretion in the proximal convoluted tubule via the human organic anion transporter system .Once in the tubular lumen, furosemide inhibits chloride transport throughout the thick ascending limb of Henle, preventing sodium reabsorption: this results in natriuresis, increased urine flow and potentially reduced tubular oxygen demand . Specially a relatively intact kidney, with preserved estimated glomerular filtration rate (eGFR) and tubular function, should respond to furosemide with a quick diuresis, whereas tubular injury can be associated with urine output that is relatively preserved at baseline, but that fails to significantly augment with a diuretic challenge. In one mixed (retrospective and prospective) study and in one randomized trial in critically ill patients admitted in intensive care with mild AKI, the furosemide stress test was able to predict the progression to severe AKI. Furthermore also the response to electrolyte excretion should predict the possible presence of AKI . In addition the renal imaging techniques by ultrasound, which are non invasive and repeatable, are considered a mandatory component of the AKI diagnostic work up . Among the available imaging technique the renal resistive index (RI) which compute the ratio between the systolic and diastolic blood velocity in the arcuate or interlobular arteries is the most common used due to the easiness and to the good reproducibility . Although the physiological and clinical significance of RI is still debated because is related to the resistance and compliance of the renal vessels and to the central hemodynamic , previous studies have shown the utility of RI to predict both the occurrence and the reversibility of AKI .

Aim of the present study is to compare the response to furosemide stress test in term in diuresis and electrolytes and of the renal index in mechanically ventilated patients at admission and after 3 days in patients with and without the presence of AKI

All consecutive mechanically ventilated patients, following an hemodynamic stabilization (mean arterial pressure of at least 65 mmHg without the need for fluid bolus and/or start or increase in the dose of vasopressors or inotropic drugs within the last 6 h), admitted to the General Intensive Care of Santi Paolo-Carlo Hospital were enrolled. Exclusion criteria were: an age < 18 years, pregnancy, hemodynamic instability (defined as mean arterial pressure (MAP)<60 mmHg), a suspected or confirmed obstructive renal failure, the presence of a chronic renal failure, as defined by a basal creatinine clearance value < 30 ml min-1 . During the study the level of sedation and the ventilatory setting were not changed.

Renal index

The renal index examination was performed by one among three dedicated physicians, who were not in charge of the patients and trained with ultrasound examinations . Doppler ultrasonography will be performed at the patient's bedside by the same trained operator using an ultrasound scanner (LogiQ7 General Electric Healthcare, UK) with a 5 Mega-hertz transducer. The Doppler measurements will be obtained from the right kidney in all patient. After visualization of the kidney in gray scale and color Doppler modes, the absence of signs of chronic renal damage will be checked. The interlobar or arcuate arteries will be localized with sonography and color Doppler mode. Blood velocities in the interlobar arteries will be recorded using pulse-wave Doppler. RI will be calculated as follow:

RI= (Peak Systolic velocity - end Diastolic Velocity)/Peak systolic velocity and average.

At least three readings will be obtained from the selected arteries, and the mean of the corresponding three renal RI determinations will be used for the study

Furosemide stress test After the ultrasonography evaluation, the patients will be tested with the Furosemide Stress Test (FST). Who will be loop-diuretic naïve will be given 1.0 mg/kg of intravenous furosemide. Because patients who are previously treated with loop diuretics within the previous 7 days are likely to have a blunted response over time compared to naïve patients, this group will receive an intravenous dose of 1.5 mg/kg) . In order to minimize the risk of hypovolemia, urine output will be replaced ml for ml each hour with Ringers lactate for six hours after the FST.

Data collection Before and after two hours of the renal index and the furosemide stress text the following clinical and laboratory data were collected: mean arterial pressure, central venous pressure, heart rate, plasma and urine amount of sodium, potassium, chloride, and arterial blood gas analysis. The urine volume was measured after one and two hours

Study Type

Observational

Enrollment (Actual)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Milan, Italy, 20152
        • ASST Santi Paolo Carlo Ospedale San Paolo

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All consecutive mechanically ventilated patients, following an hemodynamic stabilization (mean arterial pressure of at least 65 mmHg without the need for fluid bolus and/or start or increase in the dose of vasopressors or inotropic drugs within the last 6 h), admitted to the General Intensive Care of Santi PaoloCarlo Hospital

Description

Inclusion Criteria:

  • all mechanically ventilated patients

Exclusion Criteria:

  • age < 18 years
  • pregnancy
  • hemodynamic instability (defined as mean arterial pressure (MAP)<60 mmHg)
  • suspected or confirmed obstructive renal failure,
  • presence of a chronic renal failure, as defined by a basal creatinine clearance value < 30 ml min-1

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Response to furosemide stress test in patients with and without AKI
Time Frame: Two hours after furosemide stress test
Urine volume after furosemide administration,
Two hours after furosemide stress test
Urine output of sodium, potassium and chloride after furosemide stress test
Time Frame: Two hours after furosemide stress test
Determination of Urinary Sodium concentration (meq/L)
Two hours after furosemide stress test

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Renal Index in patients with and without AKI
Time Frame: At admission
Determination of the ratio between the systolic and diastolic blood velocity in the arcuate or interlobular kidney arteries
At admission

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Davide Chiumello, Professor, ASST Santi Paolo e Carlo, Ospedale San Paolo

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 24, 2019

Primary Completion (Actual)

October 20, 2019

Study Completion (Actual)

December 20, 2019

Study Registration Dates

First Submitted

December 20, 2019

First Submitted That Met QC Criteria

December 29, 2019

First Posted (Actual)

January 2, 2020

Study Record Updates

Last Update Posted (Actual)

January 2, 2020

Last Update Submitted That Met QC Criteria

December 29, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Kidney Injury

3
Subscribe